EA032263B1 - Применение ингибиторов ccr3 - Google Patents
Применение ингибиторов ccr3 Download PDFInfo
- Publication number
- EA032263B1 EA032263B1 EA201401083A EA201401083A EA032263B1 EA 032263 B1 EA032263 B1 EA 032263B1 EA 201401083 A EA201401083 A EA 201401083A EA 201401083 A EA201401083 A EA 201401083A EA 032263 B1 EA032263 B1 EA 032263B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- chloride
- treatment
- eosinophilic
- alkyl
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immunology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Structure Of Transmissions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12162937 | 2012-04-03 | ||
| EP12162937.2 | 2012-04-03 | ||
| PCT/EP2013/056864 WO2013149986A1 (en) | 2012-04-03 | 2013-04-02 | Use of ccr3-inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201401083A1 EA201401083A1 (ru) | 2015-03-31 |
| EA032263B1 true EA032263B1 (ru) | 2019-05-31 |
Family
ID=48040249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201401083A EA032263B1 (ru) | 2012-04-03 | 2013-04-02 | Применение ингибиторов ccr3 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US20130261153A1 (enExample) |
| EP (3) | EP4389217A3 (enExample) |
| JP (2) | JP2015512432A (enExample) |
| KR (5) | KR20210063481A (enExample) |
| CN (2) | CN104220073A (enExample) |
| AU (1) | AU2013245027B2 (enExample) |
| BR (1) | BR112014023795B1 (enExample) |
| CA (1) | CA2869269C (enExample) |
| CL (1) | CL2014002523A1 (enExample) |
| CY (1) | CY1123222T1 (enExample) |
| DK (1) | DK2833884T3 (enExample) |
| EA (1) | EA032263B1 (enExample) |
| ES (2) | ES2987267T3 (enExample) |
| HR (1) | HRP20201165T1 (enExample) |
| HU (1) | HUE051648T2 (enExample) |
| IL (1) | IL234262A (enExample) |
| IN (1) | IN2014DN06989A (enExample) |
| LT (1) | LT2833884T (enExample) |
| MX (1) | MX2014011786A (enExample) |
| NZ (1) | NZ628882A (enExample) |
| PH (1) | PH12014502239A1 (enExample) |
| PL (1) | PL2833884T3 (enExample) |
| PT (1) | PT2833884T (enExample) |
| RS (1) | RS60665B1 (enExample) |
| SI (1) | SI2833884T1 (enExample) |
| SM (1) | SMT202000499T1 (enExample) |
| WO (1) | WO2013149986A1 (enExample) |
| ZA (1) | ZA201406082B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| AR090566A1 (es) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| US11045284B2 (en) | 2016-11-24 | 2021-06-29 | Kirishima Seiko Co., Ltd. | Dental brace and method for attaching dental brace |
| NZ757769A (en) * | 2017-04-05 | 2025-10-31 | Alkahest Inc | Methods and compositions for treating retina-associated disease using ccr3-inhibitors |
| WO2018187503A1 (en) | 2017-04-05 | 2018-10-11 | Alkahest, Inc. | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
| JP2020536929A (ja) * | 2017-10-13 | 2020-12-17 | アルカヘスト，インコーポレイテッド | Ｃｃｒ３阻害剤を用いた、そう痒症、乾皮症、及び関連疾患を治療するための方法及び組成物 |
| AU2019271122A1 (en) | 2018-05-15 | 2020-11-12 | Alkahest, Inc. | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase |
| CA3111433A1 (en) * | 2018-09-26 | 2020-04-02 | Alkahest, Inc. | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
| JP2023529719A (ja) * | 2020-06-11 | 2023-07-11 | アルカヘスト，インコーポレイテッド | Ｃｃｒ３阻害剤を使用した網膜関連疾患の転帰改善方法 |
| US11957671B2 (en) | 2021-11-01 | 2024-04-16 | Alkahest, Inc. | Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006083390A2 (en) * | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxin-3 in eosinophilic esophagitis |
| US20090123375A1 (en) * | 2007-10-09 | 2009-05-14 | University Of Kentucky Research Foundation | CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration |
| WO2010115836A1 (en) * | 2009-04-08 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Substituted piperidines as ccr3 antagonists |
| WO2012045803A1 (en) * | 2010-10-07 | 2012-04-12 | Boehringer Ingelheim International Gmbh | Co-crystals and salts of ccr3-inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339087B1 (en) * | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| IL151499A0 (en) * | 2000-03-03 | 2003-04-10 | Cambridge Antibody Tech | Human antibodies against eotaxin and their use |
| US20020151064A1 (en) * | 2001-02-07 | 2002-10-17 | Children's Hospital Medical Center | Regulation of CCR3 expression |
| WO2010069979A1 (en) * | 2008-12-16 | 2010-06-24 | Nycomed Gmbh | Pyran derivatives as ccr3 modulators |
| EP2236520A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Stabilizing composition for immobilized biomolecules |
| US8778616B2 (en) * | 2009-05-26 | 2014-07-15 | University Of Kentucky Research Foundation | Method of using CCR3 binding agents to detect choroidal neovascularization |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| WO2020115836A1 (ja) * | 2018-12-05 | 2020-06-11 | 東浜工業株式会社 | ブロワー装置 |
-
2013
- 2013-03-27 US US13/851,564 patent/US20130261153A1/en not_active Abandoned
- 2013-04-02 PT PT137131991T patent/PT2833884T/pt unknown
- 2013-04-02 CN CN201380016333.7A patent/CN104220073A/zh active Pending
- 2013-04-02 KR KR1020217015686A patent/KR20210063481A/ko not_active Ceased
- 2013-04-02 AU AU2013245027A patent/AU2013245027B2/en active Active
- 2013-04-02 KR KR1020227031439A patent/KR20220132012A/ko not_active Ceased
- 2013-04-02 KR KR1020207011392A patent/KR20200044988A/ko not_active Ceased
- 2013-04-02 KR KR1020147027679A patent/KR20140144200A/ko not_active Ceased
- 2013-04-02 EP EP24158785.6A patent/EP4389217A3/en active Pending
- 2013-04-02 EP EP13713199.1A patent/EP2833884B1/en active Active
- 2013-04-02 HU HUE13713199A patent/HUE051648T2/hu unknown
- 2013-04-02 ES ES20174399T patent/ES2987267T3/es active Active
- 2013-04-02 SI SI201331753T patent/SI2833884T1/sl unknown
- 2013-04-02 EP EP20174399.4A patent/EP3763369B1/en active Active
- 2013-04-02 HR HRP20201165TT patent/HRP20201165T1/hr unknown
- 2013-04-02 SM SM20200499T patent/SMT202000499T1/it unknown
- 2013-04-02 PL PL13713199T patent/PL2833884T3/pl unknown
- 2013-04-02 CA CA2869269A patent/CA2869269C/en active Active
- 2013-04-02 RS RS20200868A patent/RS60665B1/sr unknown
- 2013-04-02 ES ES13713199T patent/ES2811554T3/es active Active
- 2013-04-02 LT LTEP13713199.1T patent/LT2833884T/lt unknown
- 2013-04-02 WO PCT/EP2013/056864 patent/WO2013149986A1/en not_active Ceased
- 2013-04-02 DK DK13713199.1T patent/DK2833884T3/da active
- 2013-04-02 JP JP2015503847A patent/JP2015512432A/ja active Pending
- 2013-04-02 CN CN201910406245.7A patent/CN110384699A/zh active Pending
- 2013-04-02 KR KR1020257028220A patent/KR20250133980A/ko active Pending
- 2013-04-02 EA EA201401083A patent/EA032263B1/ru unknown
- 2013-04-02 IN IN6989DEN2014 patent/IN2014DN06989A/en unknown
- 2013-04-02 MX MX2014011786A patent/MX2014011786A/es unknown
- 2013-04-02 NZ NZ628882A patent/NZ628882A/en unknown
- 2013-04-02 BR BR112014023795-6A patent/BR112014023795B1/pt active IP Right Grant
-
2014
- 2014-08-19 ZA ZA2014/06082A patent/ZA201406082B/en unknown
- 2014-08-24 IL IL234262A patent/IL234262A/en active IP Right Grant
- 2014-09-24 CL CL2014002523A patent/CL2014002523A1/es unknown
- 2014-10-03 PH PH12014502239A patent/PH12014502239A1/en unknown
- 2014-12-15 US US14/570,298 patent/US20150099783A1/en not_active Abandoned
-
2015
- 2015-11-30 US US14/953,480 patent/US20160081998A1/en not_active Abandoned
-
2017
- 2017-07-25 US US15/658,918 patent/US20170319567A1/en not_active Abandoned
- 2017-12-22 JP JP2017246173A patent/JP2018080183A/ja not_active Withdrawn
-
2020
- 2020-07-23 CY CY20201100678T patent/CY1123222T1/el unknown
- 2020-08-19 US US16/997,772 patent/US20200375971A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006083390A2 (en) * | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxin-3 in eosinophilic esophagitis |
| US20090123375A1 (en) * | 2007-10-09 | 2009-05-14 | University Of Kentucky Research Foundation | CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration |
| WO2010115836A1 (en) * | 2009-04-08 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Substituted piperidines as ccr3 antagonists |
| WO2012045803A1 (en) * | 2010-10-07 | 2012-04-12 | Boehringer Ingelheim International Gmbh | Co-crystals and salts of ccr3-inhibitors |
Non-Patent Citations (3)
| Title |
|---|
| ATSUNOBU TAKEDA, JUDIT Z. BAFFI, MARK E. KLEINMAN, WON GIL CHO, MIHO NOZAKI, KIYOSHI YAMADA, HIROKI KANEKO, ROMULO J. C. ALBUQUERQ: "CCR3 is a target for age-related macular degeneration diagnosis and therapy", NATURE, MACMILLAN JOURNALS LTD., LONDON, vol. 460, no. 7252, 9 July 2009 (2009-07-09), London, pages 225 - 30, XP002693828, ISSN: 0028-0836, DOI: 10.1038/NATURE08151 * |
| BACHERT C, WATELET J B, GEVAERT P, VAN CAUWENBERGE P.: "Pharmacological management of nasal polyposis", DRUGS, ADIS INTERNATIONAL LTD., NZ, vol. 65, no. 11, 1 January 2005 (2005-01-01), NZ, pages 1537 - 1552, XP002697885, ISSN: 0012-6667, DOI: 10.2165/00003495-200565110-00006 * |
| BLANCHARD C, ET AL.: "Eotaxin-3 and a Uniquely Conserved Gene-Expression profile in Eosinophilic Esophagitis", JOURNAL OF CLINICAL INVESTIGATION, B M J GROUP, GB, vol. 116, no. 2, 1 February 2006 (2006-02-01), GB, pages 536 - 547, XP003003549, ISSN: 0021-9738, DOI: 10.1172/JCI26679 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA032263B1 (ru) | Применение ингибиторов ccr3 | |
| JP2017081959A (ja) | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 | |
| JP2011503045A (ja) | Ｃｒｔｈ２拮抗化合物の使用 | |
| HUP0204079A2 (hu) | Szedatív hatástól mentes antihisztaminok és leukotrién hatást befolyásoló anyagok új kombinációja orrnyálkahártya-gyulladás, vagy kötőhártya-gyulladás kezelésére | |
| EA020987B1 (ru) | Ассоциация между 4-{3-[цис-гексагидроциклопента[c]пиррол-2(1h)-ил]пропокси}бензамидом и ингибитором ацетилхолинэстеразы и фармацевтические композиции, которые ее содержат | |
| EA021461B1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ | |
| RU2406499C2 (ru) | Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений | |
| WO2012133489A1 (ja) | 神経性疾患の治療又は予防のための医薬組成物 | |
| WO2016006621A1 (ja) | Ｐｇｄ２拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬 | |
| WO2020221894A1 (en) | Antiviral compounds | |
| JP5366807B2 (ja) | Ｔ細胞のＴｈ１細胞への分化抑制剤 | |
| HK40015701A (en) | Use of ccr3-inhibitors | |
| JP5978472B2 (ja) | 耳鳴患者の治療用の薬剤 | |
| US20090203701A1 (en) | Prophylactic and/or therapeutic agent for rheumatoid arthritis | |
| WO2001058488A1 (en) | Remedies for sjoegren's syndrome | |
| JPWO2007049732A1 (ja) | 関節リウマチの予防及び／又は治療法 | |
| JPWO2017126648A1 (ja) | Ｎ−［７−［（メチルスルホニル）アミノ］−４−オキソ−６−フェノキシ−４ｈ−１−ベンゾピラン−３−イル］ホルムアミドまたはその塩を含有する医薬組成物 |